✦ LIBER ✦

Efficacy of Cetuximab After Treatment with Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor—Based Chemotherapy in Metastatic Colorectal Cancer

✍ Scribed by Jeffrey A. Meyerhardt; Denise Heseltine; Shuji Ogino; Jeffrey W. Clark; Peter C. Enzinger; David P. Ryan; Craig C. Earle; Andrew X. Zhu; Charles S. Fuchs

Book ID: 119935044
Publisher: CIG Media Group, LP.
Year: 2006
Tongue: English
Weight: 147 KB
Volume: 6
Category: Article
ISSN: 1533-0028
DOI: 10.3816/ccc.2006.n.022

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Trichomegaly of the Eyelashes After Colo

Trichomegaly of the Eyelashes After Colorectal Cancer Treatment With the Epidermal Growth Factor Receptor Inhibitor Cetuximab

✍ Richard Bambury; J.A. McCaffrey 📂 Article 📅 2009 🏛 CIG Media Group, LP. 🌐 English ⚖ 174 KB

Epidermal Growth Factor Receptor Tyrosin

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in the Treatment of Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Metastatic to the Brain

✍ Jamal-Hanjani, M.; Spicer, J. 📂 Article 📅 2011 🏛 American Association for Cancer Research 🌐 English ⚖ 320 KB

Evaluation of Biologic End Points and Ph

Evaluation of Biologic End Points and Pharmacokinetics in Patients With Metastatic Breast Cancer After Treatment With Erlotinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor

✍ Rubio-Viqueira, B.; Hidalgo, M. 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 63 KB

First clinical experience of orally acti

First clinical experience of orally active epidermal growth factor receptor inhibitor combined with simplified FOLFOX6 as first-line treatment for metastatic colorectal cancer

✍ Maria Giulia Zampino; Elena Magni; Cristian Massacesi; Alberto Zaniboni; Angelo 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 148 KB 👁 1 views

## Abstract ## BACKGROUND. Gefitinib, an orally active inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase, combined with chemotherapy, has shown efficacy as second‐line treatment for advanced colorectal cancer (CRC). Gefitinib combined with FOLFOX6 (oxaliplatin plus folinic acid

Rare and complex mutations of epidermal

Rare and complex mutations of epidermal growth factor receptor, and efficacy of tyrosine kinase inhibitor in patients with non-small cell lung cancer

✍ Keam, Bhumsuk; Kim, Dong-Wan; Park, Jin Hyun; Lee, Jeong-Ok; Kim, Tae Min; Lee, 📂 Article 📅 2013 🏛 Springer 🌐 English ⚖ 225 KB

Significance of pretreatment comorbiditi

Significance of pretreatment comorbidities in elderly patients with advanced non-small-cell lung cancer treated with chemotherapy or epidermal growth factor receptor-tyrosine kinase inhibitor

✍ Kaoru Irisa; Katsuhiro Masago; Yosuke Togashi; Shiro Fujita; Yukimasa Hatachi; A 📂 Article 📅 2010 🏛 Springer US 🌐 English ⚖ 294 KB